Clinical trial registration number: www.irct.ir: IRCT201306085623N8.
Metabolic response to folate supplementation in overweight women with polycystic ovary syndrome: A randomized double-blind placebo-controlled clinical trial
Article first published online: 15 MAY 2014
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Molecular Nutrition & Food Research
Volume 58, Issue 7, pages 1465–1473, July 2014
How to Cite
Asemi, Z., Karamali, M. and Esmaillzadeh, A. (2014), Metabolic response to folate supplementation in overweight women with polycystic ovary syndrome: A randomized double-blind placebo-controlled clinical trial. Mol. Nutr. Food Res., 58: 1465–1473. doi: 10.1002/mnfr.201400033
- Issue published online: 1 JUL 2014
- Article first published online: 15 MAY 2014
- Manuscript Accepted: 11 MAR 2014
- Manuscript Revised: 28 FEB 2014
- Manuscript Received: 15 JAN 2014
- Vice-chancellor for Research, AUMS, and Iran
- Arak University of Medical Sciences. Grant Number: 92147
- Glucose metabolism;
- Lipid concentrations;
- Polycystic ovary syndrome;
This study was conducted to determine the effects of folate supplementation on metabolic profiles in obese women with polycystic ovary syndrome (PCOS).
Methods and results
This randomized double-blind placebo-controlled clinical trial was conducted among 81 obese women (weight range: 65–110 kg) aged 18–40 year old diagnosed with PCOS. Participants were randomly assigned to three groups receiving: (1) Folate-1: 1 mg/day folate supplements (n = 27); (2) Folate-5: 5 mg/day folate supplements (n = 27), and (3) placebo (n = 27) for 8 weeks. Fasting blood samples were taken at baseline and after 8 weeks’ intervention to quantify glucose metabolism and lipid concentrations. Folate supplementation (5 mg), compared with folate-1 and placebo, resulted in reduced plasma homocysteine (p-interaction = 0.009), homeostasis model of assessment-insulin resistance score (p-interaction = 0.01), and total cholesterol/HDL-C ratio (p-interaction = 0.01). Furthermore, we found a significant difference in mean change of serum total cholesterol (p-interaction = 0.01), LDL- (p-interaction = 0.007), and non-HDL-cholesterol levels (p = 0.01) in the folate-5 group compared with folate-1 and placebo.
5 mg/day folate supplementation for 8 weeks among women with PCOS had beneficial effects on metabolic profiles.